Delcath Systems, Inc.
DCTHHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Delcath Systems, Inc. focuses on Medical Devices services and products. Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The $442.2M market capitalization puts DCTH squarely in small-cap range for its industry. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Market Cap
$442.2M
Beta
0.49
P/E (TTM)
1281.00
P/E (Fwd)
-25.12
EPS (TTM)
$0.01
EPS (Fwd)
$-0.51
ROE
0.6%
ROA
-0.9%
Cash
$89.3M
Total Debt
$907,000
Free CF
$19.7M
52W Change
13.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $89.3M in cash comfortably exceeding the $907K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $19.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 0.6%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.7M (2022) to $85.2M (2025), reflecting a 3035% increase over the period.
The relatively low beta of 0.49 suggests DCTH is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, DCTH has financial flexibility that may help navigate uncertain periods. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Delcath Systems, Inc.'s trajectory.